Coherus Oncology and Zumutor Biologics have launched a Phase 1 clinical trial testing the combination of ZM008, an anti-LLT1 antibody, with LOQTORZI, a PD-1 inhibitor, in patients with various solid tumors including colorectal, lung, and head and neck cancers. This collaboration aims to explore new treatment options by targeting both innate and adaptive immune pathways, potentially benefiting patients with hard-to-treat cancers. The trial will assess safety, tolerability, and dosing in up to 45 patients in the U.S. Both companies retain commercial rights to their drugs. This study could advance personalized immunotherapy approaches and expand LOQTORZI’s indications beyond nasopharyngeal carcinoma.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
IQSTEL Inc. announced preliminary net revenue of approximately $207 million for the first half of 2026, marking a 59% increase from $130 million in the same period of 2025. The company expects to complete its acquisition of Ultranet this quarter, whi...
Chipotle is launching a $1 million burrito giveaway during the international soccer tournament final on July 19. During the second official hydration break, viewers can participate in a game on Chipotle's Instagram by tracking a lemonade-filled cup a...
Traders on the Kalshi crypto prediction market show more confidence in Stellar (XLM) than XRP for finishing 2026 with positive returns. Currently, 36% of traders bet on XLM ending the year in the green, compared to 31% for XRP. Historically, XLM has ...
SEGG Media Corporation announced that Sports.com Predict will be the Official Prediction Partner for the 2026 UIM E1 World Championship, the first all-electric raceboat series. This partnership aims to enhance fan engagement by integrating real-time ...
